The short version of visceral fat fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-05. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
== Further reading == Fetter, Steve; Cheng, E. T.; Mann, F. M. (1990). "Long-term radioactive waste from fusion reactors: Part II". Fusion Engineering and Design. 13 (2): 239–246. CiteSeerX 10.1.1.465.5945. doi:10.1016/0920-3796(90)90104-E. ISSN 0920-3796. {{cite journal}}: Cite uses deprecated parameter |citeseerx= (help) Holland, Jason P.; Sheh, Yiauchung; Lewis, Jason S. (2009). "Standardized methods for the production of high specific-activity zirconium-89". Nuclear Medicine and Biology. 36 (7): 729–739. doi:10.1016/j.nucmedbio.2009.05.007. ISSN 0969-8051. PMC 2827875. PMID 19720285. McCarthy, Deborah W.; Shefer, Ruth E.; Klinkowstein, Robert E.; Bass, Laura A.; Margeneau, William H.; Cutler, Cathy S.; Anderson, Carolyn J.; Welch, Michael J. (1997). "Efficient production of high specific activity 64Cu using a biomedical cyclotron". Nuclear Medicine and Biology. 24 (1): 35–43. doi:10.1016/S0969-8051(96)00157-6. ISSN 0969-8051. PMID 9080473.
== Contraindications == The US approval lists the thyroid C cell cancers medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia type 2 (MEN 2) as contraindications because other GLP-1 agonists are known to cause such cancers in rodents. Albiglutide causes immunogenicity in rodents, so its cancer risk could not be assessed. The European approval mentions the uncertainty about C cell cancers, but not as a contraindication.
Prenatal vitamins are dietary supplements commonly given to pregnant women to supply nutrients that may reduce health complications for the mother and fetus. Although prenatal vitamins are not meant to substitute for dietary nutrition, prenatal supplementation may be beneficial for pregnant women at risk of nutrient deficiencies because of diet limitations or restrictions. The most common components in prenatal vitamins include vitamins B6, folate, B12, C, D, E, iron and calcium. Sufficient intake of vitamin B6 can lower the risk of early pregnancy loss and relieve symptoms of morning sickness. Folate is also an essential nutrient for pregnant women to prevent neural tube defects. In 2006, the World Health Organization endorsed the recommendation for women of child-bearing age to consume 400 micrograms of folate through the diet daily if planning a pregnancy. A 2013 review found folic acid supplementation during pregnancy did not affect the mother's health other than a risk reduction on low pre-delivery serum folate and megaloblastic anemia. There is little evidence to suggest that vitamin D supplementation improves prenatal outcomes in hypertensive disorders and gestational diabetes. Evidence does not support the routine use of vitamin E supplementation during pregnancy to prevent adverse events, such as preterm birth, fetal or neonatal death, or maternal hypertensive disorders. Iron supplementation can lower the risk of iron deficiency anemia for pregnant women.
Sources: en.wikipedia.org
=== Classification === The notion that atrophic gastritis could be classified depending on the level of progress as "closed type" or "open type" was suggested in early studies, but no universally accepted classification exists as of 2017.
=== Gene content and protein synthesis === The ancestral cyanobacteria that led to chloroplasts probably had a genome that contained over 3000 genes, but only approximately 100 genes remain in contemporary chloroplast genomes. These genes code for a variety of things, mostly to do with the protein pipeline and photosynthesis. As in prokaryotes, genes in chloroplast DNA are organized into operons. Unlike prokaryotic DNA molecules, chloroplast DNA molecules contain introns (plant mitochondrial DNAs do too, but not human mtDNAs). Among land plants, the contents of the chloroplast genome are fairly similar.
Theodoros "Theo" Angelopoulos (Greek: Θεόδωρος Αγγελόπουλος; 27 April 1935 – 24 January 2012) was a Greek filmmaker, screenwriter and film producer. He dominated the Greek art film industry from 1975 on, and Angelopoulos was one of the most influential and widely respected filmmakers in the world. He started making films in 1967. In the 1970s he made a series of political films about modern Greece. Angelopoulos' films, described by Martin Scorsese as those of "a masterful filmmaker", are characterized by slight movement and distance changes, long takes, and complex, carefully composed scenes. His cinematic method is often described as "sweeping" and "hypnotic." Angelopoulos has said that in his shots, “time becomes space and space becomes time.” The pauses between action or music are important to creating the total effect. In 1998 his film Eternity and a Day went on to win the Palme d'Or at the 51st edition of the Cannes Film Festival, and his films have been shown at many of the world's esteemed film festivals.
Sources: en.wikipedia.org
=== 7 August === Sudanese prosecutors charged Hemedti and 16 other TASIS leaders with committing war crimes in El Fasher and South Kordofan. Three SLM officials (Legal Advisor Mahmoud Koreina, Economic Affairs Advisor Adam al-Nur, and Media Advisor Mustafa al-Jamil) announced the formation of a splinter faction in Uganda following their dismissal by Minni Minawi. Eighteen people were killed in RSF attacks on the villages of Markaz Al-Ziyadia and Lamina al-Ziyadiyah in North Kordofan.
Micropore particle technology consists of fine, highly porous particles that remove fluid by a combination of capillary action and evaporation. Currently, they are mainly used in wound healing, where they absorb wound exudate into their micropore structure. Here capillary flow transports the exudate away from the wound surface towards the upper surface of the MPPT layer, where a highly expanded surface area facilitates effective evaporation. The MPPT essentially acts as small micro-pumps, which, due to their small size, are able to access all crevices in the wound surface. The micro-pumping action of the particles appears to disrupt the weaponry used by bacteria and fungi against the immune system. First, the toxins and enzymes released by bacteria and fungi against the immune cells are removed, whereby the immune cells regain their function. Second, the micropumping action creates holes in the surface of biofilm. Biofilm acts as a shield that bacteria and fungi secrete to protect themselves against the immune cells. By creating holes in this shield, the immune cells become able to enter the biofilm layer and selectively remove bacteria and fungi that they do not want to be present. The result is that the immune system is able to remove an infection in a wound or on the skin. MPPT, therefore, functions as passive immunotherapy. It has no antibacterial effects, but it can remove antibiotic-resistant infections and it will not contribute to the creation of new antimicrobial resistance.
=== Available forms === Elagolix is available in the form of Orilissa 150 and 200 mg oral tablets. The 150 mg tablets are light pink, oblong, and film-coated with "EL 150" debossed on one side, while the 200 mg tablets are light orange, oblong, and film-coated with "EL 200" debossed on one side. The inactive ingredients in the tablets include mannitol, sodium carbonate monohydrate, pregelatinized starch, povidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and a distinct color additive (carmine high tint in the 150 mg tablets and iron oxide red in the 200 mg tablets).
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.